FierceMarkets, the publisher of FierceHealthcare, FierceHealthIT and FierceHealthPayer, has named Glytec a finalist in the 2016 annual Healthcare Edition of its Fierce Innovation Awards program.
One of the primary goals of the program is: To identify and reward the fiercest, most evolutionary technologies and services that can transform healthcare delivery and operational success.
Glytec’s eGlycemic Management System, or eGMS, was evaluated and scored by a judging panel on the merits of multiple criteria, including care efficiency, competitive advantage, financial impact/value, market need, patient experience/satisfaction, quality of care and patient outcomes, and overall fierceness and innovation. The company is a finalist in the Clinical Information Management category.
The judging panel includes CIOs and clinical leaders from some of the nation’s top healthcare systems, medical practices and ACOs, including Aspirus, Cook Children’s Health Care System, JFK Health System, Tufts Health Plan, Independence Blue Cross and others.
“We are very pleased that such a distinguished panel thoroughly evaluated our eGMS and selected us as a finalist. Our thanks to Fierce for providing an important service and raising awareness of emerging, impactful technologies,” said Glytec’s CEO, Bob Leonard. “Glytec’s success in helping providers reduce the risks, challenges and costs surrounding insulin dosing and glycemic management is well documented, but the magnitude of the problem is not well understood in some circles. The inadequacies and dangers of traditional approaches to insulin management can adversely affect 40% of hospitalized patients, while 50% of those on insulin therapy outside of the hospital are not at their A1c goal. The associated costs to the U.S. healthcare system are staggering. On the inpatient front, our eGMS is delivering an annualized savings as high as $10,000 per licensed bed, while on the outpatient front, reductions in patients’ A1c levels carry significant, well-quantified savings opportunities.”
Poor glucose control, due to inadequate or imprecise insulin dosing, leads to increased risk of complications, adverse drug events and mortality; longer lengths of stay; higher readmission rates; and avoidable ED visits and hospitalizations. The company’s eGMS centers on prescription software, specifically, proprietary complex insulin dosing algorithms, while also offering an array of complementary decision support tools. The system was developed with significant input from end-user providers over the company’s now 10-year history. Contrary to traditional, static approaches to insulin management, the eGMS calculates individualized doses to match the unique insulin sensitivities of each patient treated, and dynamically adjusts them over time.
“Working with health systems to produce the best possible clinical and financial outcomes is what Glytec is all about,” said the company’s Chief Medical Officer, Andrew S. Rhinehart, M.D., FACP, FACE, CDE, BC-ADM, CDTC. “Our focus is on optimizing diabetes care across the continuum, whether patients are hospitalized or at home. This is especially important as the majority of health systems transition to risk- and value-based payment programs. It’s great to see that Fierce is helping expand awareness of the fact there’s a solution available to a problem that’s been plaguing providers and patients for decades.”